Evogene Stock Forecast, Price & News

0.00 (0.00 %)
(As of 09/23/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume172,891 shs
Average Volume871,108 shs
Market Capitalization$75.19 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive EVGN News and Ratings via Email

Sign-up to receive the latest news and ratings for Evogene and its competitors with MarketBeat's FREE daily newsletter.

Evogene logo

About Evogene

Evogene Ltd. engages in the development and commercialization of a computer-biological platform for improving the development processes of products in the field of life sciences. It operates through the following segments: Agriculture, Industrial Applications, and Human Health. The Agriculture segment develops seed traits, agrochemical products, and agrobiological products to improve plant performance. The Industrial Applications focuses on the development and commercialization of improved castor bean seeds for industrial uses. The Human Health segment involves discovery and development of human microbiome-based therapeutics. The company was founded by Amir Barzilay and Hagai Karchi on October 10, 1999 and is headquartered in Rehovot, Israel.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.53 out of 5 stars

Medical Sector

1028th out of 1,351 stocks

Agricultural Chemicals Industry

11th out of 14 stocks

Analyst Opinion: 3.5Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Evogene (NASDAQ:EVGN) Frequently Asked Questions

Is Evogene a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Evogene in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Evogene stock.
View analyst ratings for Evogene
or view top-rated stocks.

What stocks does MarketBeat like better than Evogene?

Wall Street analysts have given Evogene a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Evogene wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Evogene?

Evogene saw a decrease in short interest during the month of August. As of August 31st, there was short interest totaling 587,600 shares, a decrease of 22.5% from the August 15th total of 758,600 shares. Based on an average daily volume of 372,100 shares, the short-interest ratio is currently 1.6 days. Approximately 1.5% of the shares of the stock are short sold.
View Evogene's Short Interest

When is Evogene's next earnings date?

Evogene is scheduled to release its next quarterly earnings announcement on Wednesday, November 17th 2021.
View our earnings forecast for Evogene

How were Evogene's earnings last quarter?

Evogene Ltd. (NASDAQ:EVGN) announced its quarterly earnings results on Wednesday, August, 11th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.03. Evogene had a negative trailing twelve-month return on equity of 38.88% and a negative net margin of 2,326.70%.
View Evogene's earnings history

How has Evogene's stock been impacted by Coronavirus (COVID-19)?

Evogene's stock was trading at $0.99 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, EVGN shares have increased by 194.9% and is now trading at $2.92.
View which stocks have been most impacted by COVID-19

What price target have analysts set for EVGN?

3 brokerages have issued 12 month target prices for Evogene's shares. Their forecasts range from $8.00 to $10.00. On average, they anticipate Evogene's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 208.2% from the stock's current price.
View analysts' price targets for Evogene
or view top-rated stocks among Wall Street analysts.

Who are Evogene's key executives?

Evogene's management team includes the following people:
  • Ofer Haviv, President & Chief Executive Officer
  • Dorit Kreiner, Chief Financial Officer
  • Mark Kapel, Executive Vice President-Technology
  • Eyal Emmanuel, Chief Scientific Officer
  • Nir Arbel, Chief Product Officer

What other stocks do shareholders of Evogene own?

What is Evogene's stock symbol?

Evogene trades on the NASDAQ under the ticker symbol "EVGN."

Who are Evogene's major shareholders?

Evogene's stock is owned by a variety of institutional and retail investors. Top institutional investors include ARK Investment Management LLC (16.28%), Morgan Stanley (3.50%), Morgan Stanley (3.50%), Senvest Management LLC (1.77%), JPMorgan Chase & Co. (0.75%) and PDT Partners LLC (0.65%).

Which major investors are selling Evogene stock?

EVGN stock was sold by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Senvest Management LLC, Millennium Management LLC, Susquehanna International Group LLP, PDT Partners LLC, HAP Trading LLC, Squarepoint Ops LLC, and Cubist Systematic Strategies LLC.

Which major investors are buying Evogene stock?

EVGN stock was bought by a variety of institutional investors in the last quarter, including Morgan Stanley, Morgan Stanley, Renaissance Technologies LLC, Susquehanna International Group Ltd., Occudo Quantitative Strategies LP, XTX Topco Ltd, Simplex Trading LLC, and Dimensional Fund Advisors LP.

How do I buy shares of Evogene?

Shares of EVGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Evogene's stock price today?

One share of EVGN stock can currently be purchased for approximately $2.92.

How much money does Evogene make?

Evogene has a market capitalization of $75.19 million and generates $1.04 million in revenue each year. The biotechnology company earns $-23,370,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis.

How many employees does Evogene have?

Evogene employs 131 workers across the globe.

What is Evogene's official website?

The official website for Evogene is

Where are Evogene's headquarters?

How can I contact Evogene?

Evogene's mailing address is 13 GAD FEINSTEIN STREET PARK REHOVOT P.O.B 2100, REHOVOT L3, 76121. The biotechnology company can be reached via phone at (728) 931-1900 or via email at [email protected].

This page was last updated on 9/24/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.